138 related articles for article (PubMed ID: 37683122)
1. A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies.
Sanders DB; Bartz TM; Zemanick ET; Hoppe JE; Hinckley Stukovsky KD; Cogen JD; Bendy L; McNamara S; Enright E; Kime NA; Kronmal RA; Edwards TC; Morgan WJ; Rosenfeld M
Ann Am Thorac Soc; 2023 Dec; 20(12):1769-1776. PubMed ID: 37683122
[No Abstract] [Full Text] [Related]
2. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD004197. PubMed ID: 28440853
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
Langton Hewer SC; Smyth AR
Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
[TBL] [Abstract][Full Text] [Related]
4. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.
Hoppe JE; Wagner BD; Sagel SD; Accurso FJ; Zemanick ET
BMC Pulm Med; 2017 Dec; 17(1):188. PubMed ID: 29228933
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS; Caverly LJ; Kalikin LM; Carmody LA; McClellan S; LeBar W; Sanders DB; West NE; Goss CH; Flume PA; Heltshe SL; VanDevanter DR; LiPuma JJ
Ann Am Thorac Soc; 2024 Apr; 21(4):595-603. PubMed ID: 37963297
[No Abstract] [Full Text] [Related]
7. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
8. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
10. A prospective randomised controlled mixed-methods pilot study of home monitoring in adults with cystic fibrosis.
Nash EF; Choyce J; Carrolan V; Justice E; Shaw KL; Sitch A; Mistry H; Whitehouse JL
Ther Adv Respir Dis; 2022; 16():17534666211070133. PubMed ID: 35274585
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
12. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Smith S; Rowbotham NJ; Charbek E
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD008319. PubMed ID: 30376155
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
15. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL; West NE; VanDevanter DR; Sanders DB; Beckett VV; Flume PA; Goss CH;
Contemp Clin Trials; 2018 Jan; 64():35-40. PubMed ID: 29170074
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
17. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
18. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
[TBL] [Abstract][Full Text] [Related]
19. Oral anti-pseudomonal antibiotics for cystic fibrosis.
Remmington T; Jahnke N; Harkensee C
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
[TBL] [Abstract][Full Text] [Related]
20. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
